Log in with your email address username.

×

[Articles] Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial

Although ECI was not more effective than conventional management for controlling Crohn’s disease symptoms, the risk of major adverse outcomes was lower. The latter finding should be considered hypothesis-generating for future trials. ECI was not associated with an increased risk of serious drug-related adverse events or mortality.

email